Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment

Hayashi, 2020, Mutational landscape and environmental effects in bladder cancer, Int J Mol Sci, 21, 6072, 10.3390/ijms21176072 Burger, 2013, Epidemiology and risk factors of urothelial bladder cancer, Eur Urol, 63, 234, 10.1016/j.eururo.2012.07.033 Mungan, 2000, Gender differences in stage distribution of bladder cancer, Urology, 55, 368, 10.1016/S0090-4295(99)00481-1 Guallar-Garrido, 2020, Bacillus Calmette-Guerin (BCG) therapy for bladder cancer: an update, Immunotargets Ther, 9, 1, 10.2147/ITT.S202006 Zlotta, 2009, The management of BCG failure in non-muscle-invasive bladder cancer: an update, Can Urol Assoc J, 3, S199 Ott, 2020, A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer, Cell, 183, 347, 10.1016/j.cell.2020.08.053 de Jong, 2021, Improving anti-PD-1/PD-L1 therapy for localized bladder cancer, Int J Mol Sci, 22, 2800, 10.3390/ijms22062800 Sunshine, 2015, PD-1/PD-L1 inhibitors, Curr Opin Pharmacol, 23, 32, 10.1016/j.coph.2015.05.011 Bree, 2021, Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center, World J Urol, 39, 4143, 10.1007/s00345-021-03755-w Uhlig, 2018, Gender-specific differences in recurrence of non-muscle-invasive bladder cancer: a systematic review and meta-analysis, Eur Urol Focus, 4, 924, 10.1016/j.euf.2017.08.007 Bilski, 2019, Review on gender differences in non-muscle invasive bladder cancer, Transl Androl Urol, 8, 12, 10.21037/tau.2018.11.06 McGrath, 2006, Hormonal and reproductive factors and the risk of bladder cancer in women, Am J Epidemiol, 163, 236, 10.1093/aje/kwj028 Miyamoto, 2012, Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder, BJU Int, 109, 1716, 10.1111/j.1464-410X.2011.10706.x Ben-Batalla, 2020, Influence of androgens on immunity to self and foreign: effects on immunity and cancer, Front Immunol, 11, 1184, 10.3389/fimmu.2020.01184 Moradi, 2020, The role of androgens in COVID-19, Diabetes Metab Syndr, 14, 2003, 10.1016/j.dsx.2020.10.014 Kourbanhoussen, 2021, Switching cancers: a systematic review assessing the role of androgen suppressive therapy in bladder cancer, Eur Urol Focus, 7, 1044, 10.1016/j.euf.2020.10.002 Ayari, 2016, Poly(I:C) potentiates bacillus Calmette-Guerin immunotherapy for bladder cancer, Cancer Immunol Immunother, 65, 223, 10.1007/s00262-015-1789-y Boibessot, 2022, Subversion of infiltrating macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype, Clin Transl Med., 12, e581, 10.1002/ctm2.581 Newman, 2019, Determining cell type abundance and expression from bulk tissues with digital cytometry, Nat Biotechnol, 37, 773, 10.1038/s41587-019-0114-2 Chen, 2017, Inference of immune cell composition on the expression profiles of mouse tissue, Sci Rep, 7, 40508, 10.1038/srep40508 Chenard, 2021, Sexual dimorphism in outcomes of non-muscle-invasive bladder cancer: a role of CD163+ macrophages, B cells, and PD-L1 IMMUNE CHECKPOINT, Eur Urol Open Sci, 29, 50, 10.1016/j.euros.2021.05.002 Boibessot, 2018, Sex steroids in the tumor microenvironment and prostate cancer progression, Endocr Relat Cancer, 25, R179, 10.1530/ERC-17-0493 Graff, 2016, Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer, Oncotarget, 7, 52810, 10.18632/oncotarget.10547 Guan X, Polesso F, Wang C, et al. Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature. In press. https://doi.org/10.1038/s41586-022-04522-6. Ayari, 2013, High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer, Hum Pathol, 44, 1630, 10.1016/j.humpath.2013.01.014 Fu, 2018, Dendritic cells and CD8 T cell immunity in tumor microenvironment, Front Immunol, 9, 3059, 10.3389/fimmu.2018.03059 Yang, 2017, Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer, Oncotarget, 8, 38378, 10.18632/oncotarget.16386